Breasts are made up of glandular tissue, fibrous connective tissue and fat. When glandular and fibrous tissue dominate over fat, the breast is considered dense. Around half of all women have it and it is entirely normal. The clinical significance comes from two things: dense tissue modestly raises cancer risk and it makes mammograms significantly harder to read because tumours and dense tissue look identical on the image.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “women with dense breasts aren’t in danger just because of the density itself. What matters is understanding how it affects screening and making sure the right imaging is being used to find what mammography alone might miss.”

Density is a radiological finding reported on mammography and most women don’t know their category until they read the report or ask their doctor directly.

• Four Density Categories: Radiologists grade breast density from almost entirely fatty at one end to extremely dense at the other using the BI-RADS classification system. The two higher categories are where supplemental screening becomes a clinical consideration worth discussing.
• What Causes It: Age, hormonal status, genetics and body weight all play a role. Pre-menopausal women tend to have denser breasts and density commonly reduces after menopause, though not predictably in every woman.
• The Mammogram Problem: Tumours appear white on mammography and so does dense glandular tissue. A cancer sitting inside dense breast tissue can be completely hidden by surrounding tissue, which is why standard mammography alone gives meaningfully less protection to women with breast cancer treatment risk factors and high density combined.
• Not the Same as Lumpy Breasts: Density is a radiological measurement, not something felt on examination. A woman with extremely dense tissue on imaging may feel no abnormality at all during self-examination or clinical assessment.

Most women don’t know their breast density unless they specifically ask for it to be reported, and asking is worth doing.

The short answer is yes, but the context behind that matters as much as the number.

• Real but Moderate Risk: Women in the two highest density categories have roughly two to four times the breast cancer risk of women with predominantly fatty breasts. That sounds significant but most women with dense breasts never develop cancer and density is one factor among many rather than a standalone predictor.
• Tumours Get Hidden: The masking problem is arguably more practically important than the risk elevation itself. Dense tissue obscures cancers that would be visible in a fatty breast, meaning interval cancers picked up between scheduled mammograms are more common in this group than in lower-density women.
• Supplemental Imaging Helps: Ultrasound finds additional cancers that mammography misses in dense breast tissue. MRI finds more still but is typically reserved for women who combine high density with other significant risk factors like a BRCA mutation or strong family history.
• Not a Reason to Panic: Most women with dense breasts never develop cancer and robotic cancer surgery or other treatment is only relevant if cancer is actually diagnosed. The point of knowing density is to screen smarter, not to create unnecessary anxiety about a normal anatomical variation.

Dense tissue is manageable with the right screening plan and for more on breast cancer surgery options when something is found, our blog on latissimus dorsi covers post-surgical reconstruction in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to breast cancer assessment including cases identified through dense breast supplemental screening. He heads Oncology Services across Karnataka and leads breast cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT and over 25 published clinical studies. Women with dense breasts, elevated risk or abnormal screening findings are seen here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Breast Density and Cancer Risk
2. World Health Organization — Breast Cancer Screening

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Ovarian cancer is called silent because it produces no specific early symptoms. Bloating, pelvic discomfort, frequent urination and early satiety are the four most commonly reported early indicators but all four are easily attributed to gut or urinary conditions. Most cases in India are diagnosed at Stage 3 or Stage 4. Detection before symptoms appear happens through incidental ultrasound findings, CA-125 testing in high-risk women and surveillance in confirmed BRCA1 or BRCA2 mutation carriers.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Ovarian cancer doesn’t announce itself. The women who get diagnosed early are almost always those in a surveillance programme or those whose general physician investigated persistent vague symptoms rather than treating them empirically.”

Detection relies on imaging, tumour markers and structured surveillance in high-risk women rather than population-wide screening which has not shown benefit in average-risk populations.

• Pelvic Ultrasound: Transvaginal ultrasound is the primary imaging tool for detecting adnexal masses and ovarian cancer treatment assessment at KIMS Hospital, Bangalore begins with transvaginal ultrasound combined with CA-125 for any woman presenting with persistent pelvic symptoms or an incidental adnexal finding on imaging.
• CA-125 Tumour Marker: CA-125 is elevated in most epithelial ovarian cancers but is not specific enough for population screening because it is also elevated in endometriosis, fibroids and pelvic inflammatory disease, making it most useful in combination with ultrasound findings rather than as a standalone test.
• BRCA Surveillance Protocol: Confirmed BRCA1 or BRCA2 mutation carriers who have not had risk-reducing salpingo-oophorectomy are offered six-monthly transvaginal ultrasound and CA-125 testing from age 30 to 35, recognising this surveillance has limitations but providing structured monitoring until preventive surgery is performed.
• Incidental Detection: A significant proportion of early ovarian cancers are detected incidentally on ultrasound ordered for an unrelated reason, underscoring the clinical value of investigating persistent non-specific pelvic or abdominal symptoms with imaging rather than empirical treatment.

No population-wide screening tool has demonstrated mortality benefit for ovarian cancer in average-risk women. Surveillance is reserved for confirmed high-risk individuals.

Structured ovarian cancer surveillance is clinically indicated in specific high-risk groups rather than recommended broadly.

• BRCA1 and BRCA2 Carriers: BRCA1 carriers face a 39 to 46 percent lifetime ovarian cancer risk and BRCA2 carriers face 12 to 20 percent and robotic cancer surgery or laparoscopic risk-reducing bilateral salpingo-oophorectomy between ages 35 and 40 for BRCA1 and 40 to 45 for BRCA2 remains the most effective intervention to reduce this risk.
• Strong Family History: Women with two or more first-degree relatives with ovarian or breast cancer, particularly diagnosed before age 50, warrant genetic counselling and BRCA testing before any surveillance programme is initiated rather than empirical surveillance without mutation confirmation.
• Lynch Syndrome Carriers: Lynch syndrome is associated with an 8 to 10 percent lifetime ovarian cancer risk and annual gynaecological review with transvaginal ultrasound is recommended from age 30 to 35 in confirmed carriers as part of the broader Lynch syndrome surveillance protocol.
• Persistent Vague Symptoms: Any woman over 50 with bloating, pelvic discomfort, early satiety or urinary frequency persisting for more than three weeks without a clear cause warrants immediate transvaginal ultrasound and CA-125 rather than empirical management for irritable bowel or urinary tract symptoms.

Early ovarian cancer detected through surveillance is surgically curable and for more on how specialist second opinions change cancer outcomes, our blog on second opinion covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to ovarian cancer surgery including cytoreductive surgery and HIPEC at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients with ovarian masses, high-risk genetic profiles or ovarian cancer diagnoses are seen here with every case reviewed through tumour board. Call +91 8104310753 to book your consultation.

References

1. 1. National Cancer Institute — Ovarian Cancer Screening
   2. World Health Organization — Ovarian Cancer

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Most adrenal tumours are benign adenomas that never become cancerous. Malignant transformation into adrenocortical carcinoma occurs in less than 10 percent of cases. Confirmed risk factors include tumour size over 4cm, TP53 gene mutation, IGF2 overexpression and hereditary syndromes including Li-Fraumeni and MEN1. Size is the most actionable clinical predictor. Tumours over 4cm carry significantly higher malignancy risk and require surgical removal regardless of hormonal activity.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Size and imaging characteristics tell us more than any single test. A tumour over 4cm that looks heterogeneous on CT needs to come out.”

Several biological and imaging factors distinguish adrenal tumours at risk of malignancy from those that remain benign throughout a patient’s lifetime.

• Size Over 4cm: Tumour size is the single most reliable clinical predictor of malignancy and adrenal tumour assessment at KIMS Hospital, Bangalore applies 4cm as the threshold for recommending surgical removal regardless of hormonal status.
• TP53 Gene Mutation: Germline TP53 mutations are present in up to 80 percent of paediatric adrenocortical carcinoma cases and a significant proportion of adult cases, making genetic testing important in young patients or those with Li-Fraumeni syndrome family history.
• IGF2 Overexpression: Overexpression of the insulin-like growth factor 2 gene drives malignant transformation in adrenocortical cells and is identified in the majority of adrenocortical carcinoma specimens, making it both a malignancy marker and an active therapeutic target.
• Suspicious Imaging Features: Heterogeneous appearance, irregular borders, internal necrosis and unenhanced CT attenuation above 10 Hounsfield units all indicate malignant biology rather than the uniform lipid-rich pattern typical of a benign adenoma.

Size and imaging together determine the surgical decision more reliably than hormonal testing alone.

Certain adrenal tumour characteristics make surgical removal the appropriate clinical decision before malignant transformation can be confirmed histologically.

• All Tumours Over 4cm: An adrenal tumour over 4cm warrants adrenalectomy regardless of hormonal activity and robotic cancer surgery at KIMS Hospital, Bangalore offers minimally invasive adrenalectomy with shorter hospital stay and faster recovery than open surgery for most cases.
• Growing Incidentalomas: An adrenal incidentaloma growing more than 1cm on repeat imaging within six to twelve months requires surgical removal rather than continued surveillance regardless of absolute size at detection.
• Hormonally Active Tumours: Phaeochromocytomas, aldosteronomas and cortisol-secreting adenomas carry surgical indications based on hormonal activity rather than malignancy risk alone and all require specialist evaluation before any surgical or surveillance decision is made.
• Hereditary Syndrome Carriers: Patients with confirmed MEN1, MEN2, Von Hippel-Lindau or Li-Fraumeni syndrome need more aggressive surveillance and lower size thresholds for surgical intervention because their genetic background significantly raises malignancy risk.

Any adrenal tumour with suspicious imaging, growth on surveillance or size over 4cm needs specialist assessment and for more on how cancer diagnosis is confirmed, our blog on cancer diagnosis covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to adrenal tumour surgery including robotic-assisted adrenalectomy for benign, indeterminate and malignant adrenal lesions at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT and over 25 published clinical studies. Patients with adrenal tumours wanting clarity on malignancy risk and surgical options are seen here with every case reviewed through tumour board. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Adrenal Cancer Diagnosis and Treatment
2. World Health Organization — Cancer Early Detection

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Kidney cancer under 4cm and selected tumours up to 7cm can be treated with partial nephrectomy, removing only the tumour and a clear margin of surrounding tissue while preserving the remaining functional kidney. Oncological outcomes for partial nephrectomy in T1 tumours are equivalent to radical nephrectomy removing the entire kidney. Full removal is indicated when the tumour is large, centrally located, involves the renal hilum or when partial resection cannot achieve clear margins safely. The decision is made at tumour board based on tumour size, location, the patient’s baseline kidney function and whether a minimally invasive approach is technically feasible.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Preserving the kidney matters beyond just the surgery. Patients with one functioning kidney face higher long-term cardiovascular and renal risk. Where partial nephrectomy is oncologically equivalent, it is the better operation.”

Partial nephrectomy is now the standard of care for eligible kidney tumours and is offered at high-volume oncology centres using laparoscopic or robotic-assisted techniques.

• Tumours Under 4cm: T1a tumours under 4cm are the strongest candidates for partial nephrectomy with oncological outcomes identical to radical nephrectomy and kidney cancer treatment at KIMS Hospital, Bangalore offers robotic-assisted partial nephrectomy for eligible patients as the preferred approach over open surgery.

• Tumours 4 to 7cm: Selected T1b tumours between 4 and 7cm are suitable for partial nephrectomy when the tumour is exophytic, peripherally located and not involving the collecting system, with oncological equivalence to radical nephrectomy confirmed in current evidence.

• Single Kidney Patients: Patients with a solitary kidney, bilateral kidney tumours or compromised contralateral kidney function require partial nephrectomy regardless of tumour size because radical nephrectomy in this group would leave the patient dialysis-dependent.

• Active Surveillance Option: Very small incidentally detected tumours under 2cm in elderly patients or those with significant comorbidities are managed with active surveillance including regular imaging every three to six months rather than immediate surgery.

Where partial nephrectomy is technically achievable with clear margins, it is always preferable to radical nephrectomy from a long-term kidney function and cardiovascular risk standpoint.

Radical nephrectomy remains the appropriate operation for specific tumour characteristics where partial resection cannot safely achieve the oncological goals of the operation.

• Large or Central Tumours: Tumours over 7cm or those involving the renal hilum, collecting system or renal vein make partial nephrectomy technically unreliable for achieving clear margins and robotic cancer surgery or conventional radical nephrectomy is planned when the tumour anatomy makes kidney preservation oncologically unsafe.

• Multiple Tumours: Multiple tumours distributed across the kidney make partial nephrectomy technically complex and in cases where tumour load prevents adequate remnant kidney preservation, radical nephrectomy is the safer oncological choice.

• Locally Advanced Disease: Tumours with direct invasion into adjacent structures, perinephric fat involvement confirmed on imaging or renal vein thrombus require radical nephrectomy with extended resection rather than any kidney-preserving approach.

• Poor Functional Remnant: When preoperative imaging and functional assessment show that the remnant kidney after partial nephrectomy would provide insufficient filtration based on the patient’s baseline function, radical nephrectomy with appropriate long-term renal management planning becomes the clinically safer option.

Tumour board review determines whether partial or radical nephrectomy is appropriate for each individual case and for more on specialist robotic kidney surgery, our blog on robotic surgery covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to kidney cancer surgery including robotic-assisted partial and radical nephrectomy at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients with kidney tumours wanting clarity on whether full removal is necessary are seen here with every decision through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Kidney Cancer Treatment
2. World Health Organization — Renal Cell Carcinoma

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

In Indians, the first symptoms of liver cancer are upper right abdominal discomfort, unexplained weight loss, persistent fatigue and loss of appetite. These appear in a liver already damaged by Hepatitis B, Hepatitis C or alcohol-related cirrhosis, which is why they get blamed on the underlying disease rather than a new tumour developing within it. Jaundice and abdominal swelling appear later and by that point the disease is usually advanced.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Most liver cancer patients arrive with symptoms that started months earlier. The challenge is those early symptoms look identical to the cirrhosis they already have. That’s why surveillance in high-risk patients is not optional.”

Early liver cancer symptoms are non-specific and consistently get attributed to existing liver disease rather than a new malignancy.

• Right Abdominal Discomfort: A dull ache or heaviness in the upper right abdomen that is new or has changed character from the patient’s existing liver disease symptoms is the most common early presenting complaint in hepatocellular carcinoma and liver cancer treatment assessment at KIMS Hospital, Bangalore begins with AFP testing and dedicated liver imaging for any such new symptom in a high-risk patient.

• Unexplained Weight Loss: Weight loss without dietary change in a patient with known chronic liver disease is a specific red flag that requires investigation rather than being attributed to poor appetite from cirrhosis alone.

• Loss of Appetite: Persistent anorexia that worsens progressively over weeks rather than fluctuating with liver disease activity is a symptom that distinguishes developing hepatocellular carcinoma from stable compensated cirrhosis in most clinical presentations.

• Persistent Fatigue: Fatigue that is new, worsening or disproportionate to the patient’s known liver disease severity warrants AFP and ultrasound review rather than reassurance, particularly in patients with known Hepatitis B or C infection.

These four symptoms in any patient with chronic liver disease require immediate AFP testing and liver ultrasound, not watchful waiting.

When these symptoms appear, the disease has typically moved beyond the stage where curative resection is straightforward.

• Jaundice: Yellow discolouration of the skin and eyes in a liver cancer patient indicates biliary obstruction from tumour growth or advancing liver failure and robotic cancer surgery or conventional liver resection is significantly more complex when jaundice is present at the time of surgical assessment.

• Abdominal Swelling: Ascites, fluid accumulation in the abdomen, reflects deteriorating liver function and portal hypertension from advancing tumour burden and its appearance signals that the disease has moved well beyond early-stage resectable hepatocellular carcinoma.

• Palpable Abdominal Mass: A lump felt in the upper right abdomen indicates a tumour large enough to be palpable through the abdominal wall, which in most cases corresponds to a tumour size that significantly complicates or precludes curative surgical resection.

• Shoulder Tip Pain: Right shoulder tip pain referred from an enlarging right lobe hepatic tumour irritating the diaphragm is a specific symptom of advanced hepatocellular carcinoma that patients frequently attribute to musculoskeletal causes for weeks before the correct investigation is ordered.

Surveillance with six-monthly AFP and liver ultrasound in all high-risk patients is what detects liver cancer before these later symptoms appear and for more on how cancer diagnosis is confirmed, our blog on cancer diagnosis covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to liver cancer surgery including laparoscopic and robotic-assisted hepatic resection at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients with known liver disease, abnormal AFP or suspected hepatocellular carcinoma are seen here with every case reviewed through tumour board. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Liver Cancer Symptoms and Diagnosis
2. World Health Organization — Hepatocellular Carcinoma

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Stomach cancer is one of the most commonly missed cancers in India because its early symptoms are identical to ordinary indigestion. Persistent upper abdominal discomfort, early satiety, mild nausea and unexplained weight loss are the four signs patients most frequently attribute to acidity, stress or dietary habits for months before seeking investigation. By the time the diagnosis is confirmed, most cases in India are at Stage 3 or Stage 4. The signs listed below are individually non-specific but in combination, especially in patients over 45 with a family history or H. pylori infection, they warrant urgent endoscopic evaluation rather than empirical antacid therapy.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“The patients who reach us early are almost always those whose general physician didn’t treat persistent upper abdominal symptoms with antacids alone. They investigated first. That decision is what changes the outcome.”

The symptoms of early stomach cancer are almost never dramatic. They look exactly like common gut complaints and that is precisely why they get missed for so long.

• Persistent Indigestion: Indigestion or heartburn that doesn’t improve with antacids after two to three weeks or returns consistently after stopping medication is one of the most overlooked early indicators and stomach and esophageal cancer assessment at KIMS Hospital, Bangalore begins with urgent endoscopy for anyone over 45 presenting with new-onset persistent dyspepsia.
• Early Satiety: Feeling full after eating only a small amount is a symptom patients consistently normalise as poor appetite or stress, but early satiety that appears without a dietary change and persists for more than two to three weeks is a red flag for gastric tumour causing reduced stomach capacity.
• Unexplained Weight Loss: Losing weight without intentional dietary change or increased activity is a systemic cancer symptom that applies across multiple cancer types and unexplained weight loss of more than 5 percent of body weight over six months warrants investigation regardless of how benign the patient’s other symptoms appear.
• Upper Abdominal Discomfort: A vague ache or pressure in the upper abdomen that is not clearly related to meals, doesn’t respond to antacids and persists across several weeks is consistently described by patients with early gastric cancer as something they dismissed for months before it worsened.

These four symptoms together in a patient over 45 with H. pylori history, a family history of stomach cancer or a diet high in smoked and salted foods constitute a clinical indication for immediate endoscopy.

Several additional signs appear slightly later in the early disease process and are still actionable if investigated promptly.

• Nausea Without Cause: Persistent low-grade nausea without a clear dietary or medication trigger, particularly when it appears alongside early satiety or upper abdominal discomfort, is a combination that warrants endoscopic investigation rather than empirical antiemetic treatment.
• Blood in Stool or Vomit: Vomiting blood or passing dark tarry stools indicates bleeding from the upper gastrointestinal tract and robotic cancer surgery or conventional gastric resection for surgically identified stomach cancer produces significantly better outcomes when the disease is caught before this symptom appears.
• Difficulty Swallowing: Dysphagia involving solid foods progressing to softer foods is a specific symptom of tumours at the gastro-oesophageal junction, the area where the stomach meets the oesophagus, and this symptom should never be attributed to acid reflux without endoscopic confirmation.
• Anaemia Without Explanation: Iron deficiency anaemia without a clear source of blood loss in a patient over 45 requires upper and lower gastrointestinal investigation because chronic slow bleeding from an early gastric tumour is a common presentation that gets managed as dietary anaemia for months before the correct diagnosis is made.

Early stomach cancer is treatable and surgically curable. The problem is never the surgery. It is how long the diagnosis takes and for more on how early cancer signs are investigated, our blog on early signs of cancer covers the investigation approach in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to stomach cancer surgery including laparoscopic and robotic-assisted gastrectomy at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients with persistent upper GI symptoms or a confirmed stomach cancer diagnosis are seen here with every case reviewed through tumour board. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Stomach Cancer Symptoms and Diagnosis
2. World Health Organization — Gastric Cancer

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.